Beta Glucan 500 and Biological Age and Immune Age | NCT07104929

Studies
Beta Glucan 500 and Biological Age and Immune Age

NCT07104929

Sponsor

OvationLab

Status

Completed

Last Update Posted

Feb 19, 2026Actual

Enrollment

60Actual

Phase

Phase 2

Conditions

Aging

Interventions

Beta Glucan

Countries

United States

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Feb 2026

Overall Recruitment Status or Expanded Access Status

Completed

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

May 14, 2025Actual

Primary Completion Date

Oct 9, 2025Actual

Completion Date

Oct 9, 2025Actual

First Submitted Date

Jul 28, 2025

First Submission Date that Met QC Criteria

Aug 1, 2025

First Posted Date

Aug 5, 2025Actual

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Feb 17, 2026

Last Update Posted Date

Feb 19, 2026Actual

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Is FDA Regulated Device

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

The primary purpose of this study is to evaluate the effects of BWH Labs - Beta Glucan 500 on biomarkers of biological and immune age among healthy adults.

A single-arm, open-label prospective study will be conducted evaluating the impact of 12 weeks of supplementation with two capsules daily of Beta Glucan 500 on a variety of validated markers of biological and immune age on the comprehensive TruAge panel (TruDiagnostics, Lexington, KY).

Detailed Description

Not provided

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Phase 2

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

60Actual

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Beta Glucan	Experimental		Dietary Supplement: Beta Glucan

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Beta Glucan	Dietary Supplement	12 weeks of supplementation with two capsules daily of BWH Labs Beta Glucan 500	Beta Glucan

Measure	Description	Time Frame
Epigenetic Testing		Change from baseline to 12 weeks

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Adult females or males age ≥ 40 years
Ability to read and speak English
Previous completion of a TruDiagnostic TruAge test within the past three months to enable comparison of previous biomarkers to the same biomarkers after intervention
DunedinPACE estimate of aging >0.9

Exclusion Criteria:

Current diagnosis and treatment for an autoimmune condition
Current use of beta-glucan or mushroom dietary supplement
Known allergies to beta glucan, yeast, or mushrooms
Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks
Current diagnosis of a chronic health condition (e.g., cancer, heart failure, history of pancreatitis, type I or II diabetics on insulin) deemed clinically contraindicated for the study protocol
Participants unable to provide consent

Accepts Healthy Volunteers

Yes

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

40 Years

Maximum Age

Not provided

Standard Ages

AdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Not provided

Locations

Facility	Status	City	State	ZIP	Country	Contacts
OvationLab		Richmond	Virginia	23220	United States

IPD Sharing Statement Module

Plan to Share IPD

Description

Private genetic and epigenetic data

Types

Not provided

Time Frame

Not provided

Access Criteria

Not provided

URL

Not provided

Intervention Browse Module

MeSH Terms

ID	Term
D047071	beta-Glucans

Ancestor Terms

ID	Term
D005936	Glucans
D011134	Polysaccharides
D002241	Carbohydrates

Browse Leaves

Not provided

Browse Branches

Not provided